Open Access

Polypeptide‑GalNAc‑T6 expression predicts better overall survival in patients with colon cancer

  • Authors:
    • Luis Ubillos
    • Edgardo Berriel
    • Daniel Mazal
    • Sabina Victoria
    • Enrique Barrios
    • Eduardo Osinaga
    • Nora Berois
  • View Affiliations

  • Published online on: May 10, 2018     https://doi.org/10.3892/ol.2018.8686
  • Pages: 225-234
  • Copyright: © Ubillos et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal carcinoma (CRC) is the second leading cause of cancer mortality worldwide. O‑glycosylated mucins at the cell surface of colonic mucosa exhibit alterations in cancer and are involved in fundamental biological processes, including invasion and metastasis. Certain members of the GalNAc‑transferase family may be responsible for these changes and are being investigated as novel biomarkers of cancer. In the present study the prognostic significance of GalNAc‑T6 was investigated in patients with CRC patients. GalNAc‑T6 expression was observed in all three colon cancer cell lines analyzed by reverse transcription‑polymerase chain reaction, immunofluorescence and flow cytometry. A cohort of 81 colon cancer specimens was analyzed by immunohistochemical staining using MAb T6.3. It was demonstrated that GalNAc‑T6 was expressed in 35/81 (43%) cases of colon cancer but not in the normal colonic mucosa. No association was observed with the clinical‑pathologic parameters. However, patients expressing GalNAc‑T6 had a significantly increased overall survival (median, 58 months; P<0.001) compared with GalNAc‑T6 negative patients, especially those with advanced disease. These results suggest that GalNAc‑T6 expression predicts an improved outcome in patients with CRC. The molecular mechanism underlying the less aggressive behavior of colon cancer cells expressing GalNAc‑T6 remains to be elucidated.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ubillos L, Berriel E, Mazal D, Victoria S, Barrios E, Osinaga E and Berois N: Polypeptide‑GalNAc‑T6 expression predicts better overall survival in patients with colon cancer. Oncol Lett 16: 225-234, 2018
APA
Ubillos, L., Berriel, E., Mazal, D., Victoria, S., Barrios, E., Osinaga, E., & Berois, N. (2018). Polypeptide‑GalNAc‑T6 expression predicts better overall survival in patients with colon cancer. Oncology Letters, 16, 225-234. https://doi.org/10.3892/ol.2018.8686
MLA
Ubillos, L., Berriel, E., Mazal, D., Victoria, S., Barrios, E., Osinaga, E., Berois, N."Polypeptide‑GalNAc‑T6 expression predicts better overall survival in patients with colon cancer". Oncology Letters 16.1 (2018): 225-234.
Chicago
Ubillos, L., Berriel, E., Mazal, D., Victoria, S., Barrios, E., Osinaga, E., Berois, N."Polypeptide‑GalNAc‑T6 expression predicts better overall survival in patients with colon cancer". Oncology Letters 16, no. 1 (2018): 225-234. https://doi.org/10.3892/ol.2018.8686